Portal Insulin CEO Richard Berenson

Rick is CEO of Portal Insulin LLC, a development-stage biotechnology company developing stabilized insulin formulations for intraperitoneal delivery. He also serves as President of Cardathea (electric field imaging for guiding placement of pacing leads) and as strategic CFO of SimulConsult Inc. (diagnostic decision support software for rare diseases). He is a member of the boards of iQure, Inc. (novel drug for epilepsy), Massachusetts Medical Angels (premier early-stage life sciences stage investment group in Boston), and the Freedom Trail Foundation (history tourism).

Rick is a serial entrepreneur who has served as CEO or COO of eleven other companies in consumer products manufacturing, knowledge management, new media, entertainment industry technology, manufacturing software, healthcare information and services, healthcare market research, anti-infectives drug discovery, diagnostic reference laboratory services, and cancer immunotherapeutics. Most recently, he spent 10 years as CEO of Thermalin Inc. (novel insulin analogs), where he assembled a world-class team of scientists, consummated industry partnerships with Sanofi and Eli Lilly and raised $64M in equity and non-dilutive support Rick is Managing Director of Venzyme Catalyst, LLC, a consultancy that provides executive services and strategic guidance to early-stage companies.

He has raised or helped raise more than $99M in private and non-dilutive capital for his own and client companies. A former McKinsey & Company consultant who started his post-graduate career as a member of technical staff at AT&T Bell Laboratories, Rick received a J.D.-M.B.A. from Harvard Business and Law Schools in 1984 and is a magna cum laude graduate in Economics from Harvard College.